Transire Bio receives Bridge Proof of Concept Fellowship
Transire Bio represented by our co-founder David Klein Cerrejon, receives the Bridge Proof of Concept Fellowship! The BRIDGE funding program is a cooperation between Innosuisse – Swiss Innovation Agency and the SNSF Swiss National Science Foundation.
Transire Bio in ftmedien
Story about Transire Bio featured in ftmedien! Read the complete article at Saugnäpfe statt Nadelstiche – ftmedien.ch Gesundheit.
Transire Bio wins the Venture Kick Stage II
Transire Bio receives additional CHF 40’000 and advances to the next stage of Venture Kick!
Venture Kick is a philanthropic initiative with a three-stage funding model initiated to financially support Swiss startups to kick-start their entrepreneurial journey. Moreover, Venture Kick provides media exposure, credibility, kickers camps, and access to a broad network of industry experts and investors to the selected projects.
Read the announcement at CHF 40,000 for technologies to uncover underground corrosion, restoration of soil health, and painless delivery of injectable drugs (venturekick.ch) and check our profile on their website Transire Bio – Venture Kick. Learn more about the Venture Kick at Venture Kick – CHF 150,000 to kick your startup.
OctoPatch® and Transire Bio featured in the ETH News
Our main publication is out and ETH News published an exciting article covering our innovation and Transire Bio!
Read the full article at https://ethz.ch/en/news-and-events/eth-news/news/2023/09/how-a-suction-cup-delivers-medications-to-the-bloodstream.html?utm_source=linkedin&utm_medium=ETH+Z%C3%BCrich&utm_content=9f726d3d48014c3fb595fc0e1f853557-4923&utm_campaign=HK_Grund_Forschung.
OctoPatch® in Science Translational Medicine
The scientific background of our technology is published in Science Translational Medicine, a prestigious peer-reviewed journal.
Read the full article at http://www.science.org/doi/10.1126/scitranslmed.abq1887.
For free access, check the link in the news on the Drug Formulation and Delivery webpage Octopus-inspired buccal patch for peptide delivery – Drug Formulation & Delivery | ETH Zurich.
Transire Bio at ETH Industry Day 2023
Our co-founder Dr. Nevena Paunović, gave a presentation at ETH Industry Day 2023 in the section Health & Food.
At our booth, Nevena and David had exciting discussions with pharmaceutical companies, investors and ETH members.
Read more about the event at ETH Industry Day | ETH Zurich.
Transire Bio wins 3rd prize at 3Pi competition 2023
Ten ETH Pioneer Fellows Pitched their projects in Pi (3.14) minutes.
Transire Bio represented by our co-founder Nevena won the 3rd prize!
Read more about the event at 3Pi Competition | ETH Zurich.
Transire Bio wins the Venture Kick Stage I
Transire Bio receives CHF 10’000 and advances to the next stage of Venture Kick!
Venture Kick is a philanthropic initiative with a three-stage funding model initiated to financially support Swiss startups to kick-start their entrepreneurial journey. Moreover, Venture Kick provides media exposure, credibility, kickers camps, and access to a broad network of industry experts and investors to the selected projects.
Read the announcement at Startups developing AI-based nutritional tracking, decarbonized amonia production, a technology to uncover underground corrosion, restoration of soil health, and painless delivery of injectable drugs each win CHF 10,000 (venturekick.ch) and check our profile on their website Transire Bio – Venture Kick. Learn more about the Venture Kick at Venture Kick – CHF 150,000 to kick your startup.
Transire Bio starts with Innosuisse Initial Coaching
Transire Bio receives a voucher for the Innosuisse Initial Coaching! The voucher can be used for coaching sessions with Innosuisse accredited coaches with expertise in biotech, medtech, financing, legal and other startup relevant topics. Innosuisse is the Swiss Innovation Agency with the goal to promote science-based innovations aligned with the economic and societal interests of Switzerland.
Learn more about Innosusse at https://www.innosuisse.ch/inno/en/home.html.
Innosuisse innovation grant without an implementation partner for R&D activities related to OctoPatch®
With the support of Innosuisse, we will further optimize our formulation and develop a zero-waste OctoPatch®, which will help us meet our sustainability goals. For these tasks, the group of Drug Formulation and Delivery at ETH received the Innosuisse innovation grant worth CHF 305’624.00. Innosuisse is the Swiss Innovation Agency with the goal to promote science-based innovations aligned with the economic and societal interests of Switzerland.
Read the summary of the project at https://www.aramis.admin.ch/Texte/?ProjectID=53460. Learn more about Innosusse at https://www.innosuisse.ch/inno/en/home.html.